Septerna (NASDAQ:SEPN) Director Alan Ezekowitz Sells 81,820 Shares of Company Stock

Septerna, Inc. (NASDAQ:SEPN) Director Alan Ezekowitz sold 81,820 shares of the stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $48.09, for a total transaction of $3,934,723.80. Following the completion of the transaction, the director owned 35,600 shares in the company, valued at $1,712,004. This trade represents a 69.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Septerna Price Performance

Shares of SEPN traded up $0.74 on Friday, reaching $42.60. The company’s stock had a trading volume of 337,791 shares, compared to its average volume of 421,986. The stock’s 50 day simple moving average is $40.46 and its two-hundred day simple moving average is $33.12. The stock has a market capitalization of $2.03 billion, a P/E ratio of -33.02 and a beta of 2.20. Septerna, Inc. has a 12-month low of $19.69 and a 12-month high of $53.34.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, November 9th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.15). Septerna had a negative net margin of 61.29% and a negative return on equity of 14.98%. The business had revenue of $18.88 million for the quarter, compared to analysts’ expectations of $20.78 million. Analysts expect that Septerna, Inc. will post -1.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on SEPN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research report on Thursday, October 15th. Stifel Nicolaus raised their target price on Septerna from $49.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday. HC Wainwright lifted their target price on Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Guggenheim boosted their price target on Septerna from $51.00 to $65.00 and gave the company a “buy” rating in a report on Friday, November 6th. Finally, Wells Fargo & Company boosted their price target on Septerna from $50.00 to $61.00 and gave the company an “overweight” rating in a report on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $56.44.

Septerna News Roundup

Investors following SEPN have been watching these news items:

• Positive Sentiment: Analysts raised expectations for Septerna’s SEP-479 program, prompting a fair-value increase. The more optimistic outlook could support investors’ expectations for the company’s pipeline. Septerna fair-value lift as analysts raise SEP-479 expectations
• Positive Sentiment: Stifel Nicolaus raised its price target on SEPN, while another report said the shares reached a new 52-week high following an analyst upgrade—signals that may reinforce positive sentiment. Stifel Nicolaus price-target boost Shares reach a 52-week high following analyst upgrade
• Neutral Sentiment: HC Wainwright maintained its Buy rating and $60 target. Its revisions were mixed: it raised its FY2027 loss estimate to a smaller loss of $1.34 per share, but lowered its FY2026 estimate to a larger loss of $1.48 per share and also cut estimates for Q4 2026 and Q1 2027. Septerna analyst and stock information

Hedge Funds Weigh In On Septerna

Several large investors have recently added to or reduced their stakes in the company. TRV GP V LLC purchased a new stake in shares of Septerna in the second quarter worth $208,160,143. TRV GP VI LLC purchased a new position in shares of Septerna during the 2nd quarter valued at $141,048,460. BlackRock Inc. purchased a new position in shares of Septerna during the 2nd quarter valued at $64,706,000. Jupiter Topco LLC purchased a new position in shares of Septerna during the 2nd quarter valued at $43,723,000. Finally, Primecap Management Co. CA bought a new position in Septerna in the 2nd quarter worth $39,096,000.

Septerna Company Profile

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.